Shao-Wei Weng, Tzu-Lun Huang, P. Su, P. Chang, Jiakui Wang
{"title":"Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy.","authors":"Shao-Wei Weng, Tzu-Lun Huang, P. Su, P. Chang, Jiakui Wang","doi":"10.21037/JES.2016.04.16","DOIUrl":null,"url":null,"abstract":"The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.","PeriodicalId":12096,"journal":{"name":"眼科学报","volume":"21 1","pages":"201-3"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"眼科学报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/JES.2016.04.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.
期刊介绍：
Eye science was founded in 1985. It is a national medical journal supervised by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and hosted by Sun Yat-sen University Zhongshan Eye Center (in October 2020, it was changed from a quarterly to a monthly, with the publication number: ISSN: 1000-4432; CN: 44-1119/R). It is edited by Ge Jian, former dean of Sun Yat-sen University Zhongshan Eye Center, Liu Yizhi, director and dean of Sun Yat-sen University Zhongshan Eye Center, and Lin Haotian, deputy director of Sun Yat-sen University Zhongshan Eye Center, as executive editor. It mainly reports on new developments and trends in the field of ophthalmology at home and abroad, focusing on basic research in ophthalmology, clinical experience, and theoretical knowledge and technical operations related to epidemiology. It has been included in important databases at home and abroad, such as Chemical Abstract (CA), China Journal Full-text Database (CNKI), China Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Journal Database (VIP).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
